Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JKN2401 injection for moderate-to-severe COPD
CTR20255170Phase 3Active
- Sponsor
- Quxin Biopharmaceutical
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of JKN2401 in chronic obstructive pulmonary disease (COPD), sponsored by Quxin Biopharmaceutical. Started Dec 2025; status: active.
02
Drugs
JKN2401
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20255170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255170.